We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

IonGate Automates Active Substance Research on Transporters

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

IonGate Biosciences GmbH announces the market launch of SURFE2R Workstation.

According to Company, for the first time a workstation allows a highly automated and efficient drug research on transporters and ion channels.

With this SURFE2R Workstation, IonGate provides the next automated device generation after SURFE2R One and the first to measure 96 sensor array plates. It is especially conceived for applications with higher throughput in pharmaceutical drug screening. The analytic methods enable the screening of defined compound libraries and the secondary screening of promising substances with high data quality.

The SURFE2R Technology (SURFace Electrogenic Event Reader) permits the direct functional characterization of transporters. This technique also offers data quality than fluorescence-based assays and is substantially simpler as compared to radioactive methods. Core of the technology is a special biosensor developed by IonGate which measures the activity of transporters through electric charges with a reproducibly high quality.

Transporters, amongst others, play a fundamental role in information processing and the metabolism of any organism. In addition, they also influence the bioavailability of drugs. With the SURFE2R Technology, IonGate offers lab automation that is now paving the way to investigate this new target class fast.

Internationally IonGate will introduce its SURFE2R Workstation at the Drug Discovery & Development of Innovative Therapeutics (DDT) from the 6th to the 9th of August 2007 in Boston, USA.